Clinical Trials Browser

DMAC2L protein, human × Thoracic × 30 days × Clear all

NCT07463677 2026-03-11

Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms